NCT00385216

Brief Summary

Third molar surgery is complicated by pain and swelling for several days after surgery. Non-steroidal antiinflammatory drugs have been useful in combination with opioids for treatment. Nicotine has antiinflammatory and pain relieving properties. We will use nicotine or placebo as a nasal spray before surgery to determine whether nicotine affects pain or inflammation.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
20

participants targeted

Target at below P25 for phase_4

Timeline
Completed

Started Jul 2004

Longer than P75 for phase_4

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 1, 2004

Completed
2.3 years until next milestone

First Submitted

Initial submission to the registry

October 5, 2006

Completed
4 days until next milestone

First Posted

Study publicly available on registry

October 9, 2006

Completed
2.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2009

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2009

Completed
1.4 years until next milestone

Results Posted

Study results publicly available

October 27, 2010

Completed
Last Updated

September 19, 2024

Status Verified

September 1, 2024

Enrollment Period

4.8 years

First QC Date

October 5, 2006

Results QC Date

October 1, 2010

Last Update Submit

September 5, 2024

Conditions

Keywords

Third MolarPain

Outcome Measures

Primary Outcomes (1)

  • Pain Reported by Patient

    Pain were reported on the numerical rating scale for pain (NRS) with 0=no pain and 10=worst pain.

    Up to 1 day

Secondary Outcomes (5)

  • Heart Rate

    5 days

  • Systolic Blood Pressure

    5 days

  • Diastolic Blood Pressure

    5 days

  • Difference in Amount of Nausea Reported

    5 days

  • Difference in Number of Hydrocodone 5 mg Acetaminophen 325 mg Tablets Taken After Surgery

    5 days

Study Arms (2)

Nicotine nasal spray

ACTIVE COMPARATOR

In one sitting the subject will receive a nicotine nasal spray, 3 mg, one application.

Drug: Nicotine

Placebo spray

PLACEBO COMPARATOR

In one sitting the subject will receive a placebo nasal spray (0 mg), one application.

Other: Placebo

Interventions

Nicotine nasal spray 3mg x 1 before surgery

Also known as: Nasal spray, nicotine
Nicotine nasal spray
PlaceboOTHER

Placebo nasal spray 0mg x 1 before surgery

Also known as: Nasal spray, placebo
Placebo spray

Eligibility Criteria

Age18 Years - 60 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • over 18
  • molars to be removed

You may not qualify if:

  • pregnant
  • lactating
  • chronic pain
  • narcotic use
  • asthma
  • ex-smokers

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Columbia University

New York, New York, 10032, United States

Location

MeSH Terms

Conditions

CrowdingPain

Interventions

NicotineTobacco Use Cessation DevicesNasal Sprays

Condition Hierarchy (Ancestors)

Spatial BehaviorBehaviorNeurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Solanaceous AlkaloidsAlkaloidsHeterocyclic CompoundsPyridinesHeterocyclic Compounds, 1-RingTherapeuticsAerosolsColloidsComplex MixturesDosage FormsPharmaceutical Preparations

Results Point of Contact

Title
Pamela Flood, MD
Organization
Columbia University

Study Officials

  • Pamela Flood, MD

    Columbia University

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
Yes

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
CROSSOVER
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 5, 2006

First Posted

October 9, 2006

Study Start

July 1, 2004

Primary Completion

May 1, 2009

Study Completion

June 1, 2009

Last Updated

September 19, 2024

Results First Posted

October 27, 2010

Record last verified: 2024-09

Locations